Navigation Links
Approved Lymphoma Drug Shows Promise in Early Tests Against Bone Cancer
Date:11/5/2009

ROCHESTER, N.Y., Nov. 5 /PRNewswire-USNewswire/ -- A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer. The study drug, Bortezomib, was found to be effective against bone cancer in human cancer cell studies and in mice. While key experiments were in animals, the cancer studied closely resembled the human form and the drug has already been proven to be safe in human patients.

In the current study, researchers sought to use Bortezomib (Velcade(R)) against osteosarcoma, an aggressive cancer that starts in bone, spreads quickly and responds poorly to current chemotherapies. The drug, a proteasome inhibitor developed by Millennium Pharmaceuticals and Johnson & Johnson, was approved by the FDA for the treatment of a rare, aggressive form of non-Hodgkin's lymphoma in 2006 and for multiple myeloma in 2008.

"Our most clinically relevant finding is that a drug already proven safe and effective in treating the most common cancers of the blood may be equally effective in suppressing bone cancer," said Roman Eliseev, M.D., Ph.D., research assistant professor within the Center for Musculoskeletal Research and the James P. Wilmot Cancer Center, both within the University of Rochester Medical Center. "Bortezomib caused osteosarcoma cells to self destruct, and prevented their spread. While further studies are needed, our findings suggest that this drug may represent a new treatment option for a devastating disease and an effective complement to current chemotherapies."

Reason to Hope

Eliseev's lab and others have shown that a protein complex called
'/>"/>

SOURCE University of Rochester Medical Center
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Solos Endoscopy, Inc.s FDA Approved MammoView(TM) Product Line to Obtain CE Mark
2. Minimally Invasive Device Approved to Treat Liver Cancer, Fibroids, Tumors, and Bleeding
3. FDA Acts to Halt Marketing of Unapproved Codeine Sulfate Tablets
4. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
5. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
6. United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food
7. ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients
8. Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery
9. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
10. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
11. Pioneering Diamyd(R) Study to Prevent Childhood Diabetes Approved
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015  Johnson & Johnson (NYSE: ... at 10 a.m. (Eastern Time) on Thursday, April 23, 2015, ... Investors and other interested parties may ... the Company,s website at www.jnj.com and clicking on ... the meeting will be made available a few hours after ...
(Date:3/27/2015)... March 27, 2015  WebMD Health Corp. ... of health information, today announced an exclusive ... National Action Plan for Combating Antibiotic-Resistant Bacteria ... the urgency and importance of addressing antibiotic-resistant ... global health.    The WebMD interview, ...
(Date:3/26/2015)... "Whether it,s our family, our friends, all ... In a single sentence, Dr. Anthony Coyle , ... Centers for Therapeutic Innovation (CTI), sums up ... America,s biopharmaceutical companies. CTI,s unique model ... foundations and the National Institutes of Health (NIH) to ...
Breaking Medicine Technology:Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2
... provides the foundation for improving understanding of N-myc,gene,s ... when,retinoblastoma forms, MEMPHIS, Tenn., Jan. 16 ... Children,s Research Hospital helps answer a,long-standing mystery about ... deeper understanding of how genes coordinate the complex ...
... ... in Phase I Studies -, RESEARCH TRIANGLE PARK, ... and commercializing innovative,treatments for diseases of the central nervous system, today ... its,lead candidate for the treatment of depression and anxiety. Tyrima is ...
Cached Medicine Technology:St. Jude Defines Eye Cancer Gene's Role in Retinal Development 2St. Jude Defines Eye Cancer Gene's Role in Retinal Development 3CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM) 2CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM) 3
(Date:3/28/2015)... a bite of warm, gooey pepperoni pizza, and your ... stomach, ready to break down your meal. In many ... amok, triggering a burning sensation in the chest. Heartburn ... Americans have heartburn at least once a month. The ... can be stopped. , Heartburn or acid reflux symptoms ...
(Date:3/28/2015)... March 28, 2015 Emergency Medical Care ... care in Manhattan, recently commemorated its three-year anniversary of ... Manhattan. In addition to 24-hour urgent care, Emergency Medical ... , At this time, Emergency Medical Care’s Urgent ... asthma, chest pain, eye injuries, ear infections, fevers, insect ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Pitching speed, ... a history of shoulder and elbow injuries, according to new ... Medicine’s ( AOSSM ) Specialty Day. , “Our findings indicate ... a 20% increase in likelihood of a history of injury, ... with a 12% increase likelihood of a history of injury, ...
(Date:3/28/2015)... Early surgery may not be the best ... injuries, according to new research from Tripler Army Medical ... Society for Sports Medicine’s ( AOSSM ) Specialty Day, ... was not performed. , The final study group focused ... 17 receiving non-surgical therapy. Of the non-surgery group, 8 ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Association Annual Conference to be held April 10-11, ... Columbus, OH. , The OPTA Annual Conference ... products and services. , Representatives from Aureus ...
Breaking Medicine News(10 mins):Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
... expenses and largely unable to meet essential future ones, such ... poll from The SCAN Foundation and the UCLA Center for ... second year, sought to better understand health and long-term care ... and the rising number of Californians older than 60, a ...
... TUESDAY, Aug. 16 (HealthDay News) -- The amount of hidden ... indicator of cardiac disease risk than a bulging waistline or ... behind the rib cage -- known as pericardial fat -- ... that causes atherosclerosis and can trigger heart attacks, the leading ...
... General Medical Sciences of the National Institutes of Health ... molecular cell biology in Wayne State University,s College of ... the alteration of chromatin regulates cellular division and growth. ... cancer treatments currently undergoing clinical trials. Chromatin is ...
... associate professor at the School of Public Health and ... of just 21 Robert Wood Johnson Foundation (RWJF) Executive ... of nurse leaders from across the country chosen to ... to enhance nurse leaders, effectiveness in improving the United ...
... By Steven Reinberg HealthDay Reporter , MONDAY, Aug. 15 ... may contribute to a shortened lifespan, a new study suggests. ... day of TV lived, on average, nearly five years less ... television watched after age 25, lifespan fell by 22 minutes, according ...
... D and its derivatives have a protective effect against ... field of colon cancer, numerous experimental and epidemiological studies ... its derivatives inhibit the growth of cancerous cells. Researchers ... collaboration with the Alberto Sols Institute of Biomedical Research ...
Cached Medicine News:Health News:Poll finds two-thirds of California voters unprepared for costs of growing older 2Health News:Poll finds two-thirds of California voters unprepared for costs of growing older 3Health News:Poll finds two-thirds of California voters unprepared for costs of growing older 4Health News:The Fattier Your Heart, the Greater Your Heart Disease Risk 2Health News:The Fattier Your Heart, the Greater Your Heart Disease Risk 3Health News:NIH awards WSU researcher $1.39M to study chromatin's role in cell division 2Health News:UofL's Ruth Carrico selected for National Nurse Fellowship 2Health News:UofL's Ruth Carrico selected for National Nurse Fellowship 3Health News:UofL's Ruth Carrico selected for National Nurse Fellowship 4Health News:Too Much TV May Take Years Off Your Life 2Health News:Too Much TV May Take Years Off Your Life 3Health News:Confirmation that vitamin D acts as a protective agent against the advance of colon cancer 2Health News:Confirmation that vitamin D acts as a protective agent against the advance of colon cancer 3
Irrigating Capsulorhexis Cystotome. Formed blunt tip, 25 g. Overall length 22 mm. 5/box....
Irrigating Cystotome, formed, 23 g., 12 mm curved tip. Overall length 14 mm. 5/box....
Retrobulbar Needle, 25 g. Atkinson style bevel. Overall length 38 mm. 5/box....
Peribulbar Needle, 23 g. Atkinson style bevel. Overall length 31 mm. 5/box....
Medicine Products: